CLINICAL TRIALS FOR AGE 12 YEARS AND OLDER:

TRIAL 1: A double-blind, placebo-controlled, Phase 3 trial in patients heterozygous for the F508del mutation and a specific mutation1,2

Study Design
 

RANDOMIZED

1:1

BASELINE

WEEK 24a

TRIKAFTA®
(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
200 mg/100 mg/150 mg qam and 150 mg qpm with fat-containing food (N=200)

Placebo
q12h with fat-containing food (N=203)

WEEK 4
(primary endpoint)

All patients remained on their standard-of-care CF therapies.1

aAll patients who completed the study were eligible to roll over into a 192-week, open-label extension study.1,3

 

Key inclusion criteria1,2b

  • Confirmed CF diagnosis, clinically stable, and at least 12 years of age
  • Heterozygous for the F508del mutation and one of ~200 other mutations in the CFTR gene that resulted in either:
    • No CFTR protein
    • A CFTR protein that lacks baseline activity and is not responsive to ivacaftor and tezacaftor/ivacaftor
  • ppFEV1 between 40% and 90% at screening

bKey exclusion criteria included clinically significant cirrhosis with or without portal hypertension, a history of colonization with organisms associated with a more rapid decline in pulmonary status (including, but not limited to, Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium abscessus), and solid organ or hematologic transplantation.1,2

 

Primary endpoint1

  • Absolute change in ppFEV1 from baseline at Week 4
    • Preplanned interim analysis was conducted after ≥140 patients completed the Week 4 visit and ≥100 patients completed the Week 12 visit
    • There were 403 patients included in the preplanned interim analysis at Week 4

SELECTED KEY SECONDARY ENDPOINTS1c

FROM BASELINE THROUGH WEEK 24:

  • Absolute change in ppFEV1
  • Number of pulmonary exacerbationsd
  • Absolute change in sweat chloride
  • Absolute change in CFQ-R Respiratory Domain score

FROM BASELINE AT WEEK 24:

  • Absolute change in BMI

FROM BASELINE AT WEEK 4:

  • Absolute change in CFQ-R Respiratory Domain score
ᶜA hierarchical testing procedure was performed for key secondary endpoints. For an endpoint to be significant, both it and all previous tests in the hierarchy had to achieve P<0.05.2 
ᵈIn the trial, a pulmonary exacerbation was defined as a change in antibiotic therapy (IV, inhaled, or oral) as a result of 4 or more of 12 prespecified sinopulmonary signs/symptoms.1

 

 

Baseline characteristics in Trial 14
TRIKAFTA
Placebo
Sex, female, %
48.0
48.3
Mean age, years (range)
25.6 (12.1-59.9)
26.8 (12.3-64.0)
Mean BMI, kg/m2 (range)
21.49 (15.01-30.86)
21.31 (14.42-33.80)
Mean ppFEV1 (range)
61.6 (33.8-97.1)
61.3 (32.3-93.7)
Mean SwCI, mmol/L (range)
102.3 (22.5-156.0)
102.9 (68.5-137.0)
Back to Top

Summary of Efficacy Results

Significant improvement in lung function at Week 4, sustained through Week 241

PRIMARY ENDPOINT

ABSOLUTE CHANGE IN ppFEV1 FROM BASELINE AT WEEK 4
13.8

Percentage
Points

SIGNIFICANT IMPROVEMENT VS PLACEBO

in mean absolute change in ppFEV1 from baseline at Week 4 based on preplanned interim analysis (95% CI: 12.1, 15.4; P<0.0001)

SECONDARY ENDPOINT

ABSOLUTE CHANGE IN ppFEV1 FROM BASELINE THROUGH WEEK 241 

Increase

14.3

Percentage
Points

IMPROVEMENT VS PLACEBO
based on the average of Weeks 4, 8, 12, 16, and 24 
(95% CI:12.7, 15.8; P<0.0001)

  • Improvements in ppFEV1 were seen regardless of age, ppFEV1 at baseline, geographic region, and sex

In Trial 1, mean baseline ppFEV₁ was 61.6 percentage points (range: 33.8, 97.1) for patients receiving TRIKAFTA and 61.3 percentage points (range: 32.3, 93.7) for patients receiving placebo.4

Collapse

Back to Top

Reduction in rate of pulmonary exacerbations through Week 241 

SECONDARY ENDPOINT

Annualized Rate of Pulmonary Exacerbationse,f

Decrease

63%

REDUCTION THROUGH WEEK 24
(RR: 0.37, [95% CI: 0.25, 0.55]; P<0.0001)

ᵉIn Trial 1, the number of pulmonary exacerbation events was 113 (0.98) for placebo vs 41 (0.37) for TRIKAFTA.1
f
In Trial 1, the number of pulmonary exacerbations is expressed as a rate over 48 weeks based on 24 weeks of observation.1

Collapse

Back to Top

ADDITIONAL ENDPOINTS IN TRIAL 15,6

71%

REDUCTION in event Rate leading to HOSPITALIZATION (32 events for placebo vs 9 events for TRIKAFTA [RR: 0.29, 95% CI: 0.14, 0.61])

78%

REDUCTION in event RATE leading to IV ANTIBIOTIC USE (51 events for placebo vs 11 events for TRIKAFTA [RR: 0.22, 95% CI: 0.11, 0.43])

  • Power for additional endpoints was limited. Analysis of additional endpoints was not adjusted for multiplicity. These additional endpoints are not included in the TRIKAFTA full Prescribing Information
Back to Top

Significant reduction in sweat chloride through Week 241,5 

SECONDARY ENDPOINT

MEAN ABSOLUTE CHANGE IN SWEAT CHLORIDE

Decrease

41.8

mmol/L REDUCTION
vs placebo through Week 24 (95% CI: -44.4, -39.3; P<0.0001)

In Trial 1, mean baseline sweat chloride was 102.3 mmol/L (range: 22.5, 156.0) for patients receiving TRIKAFTA and 102.9 mmol/L (range: 68.5, 137.0) for those receiving placebo.4

Collapse

Back to Top

Significant improvement in CFQ-R Respiratory Domain score at Week 4, maintained through Week 241,5

SECONDARY ENDPOINT

ABSOLUTE CHANGE FROM BASELINE IN CFQ-R RESPIRATORY DOMAIN SCORE THROUGH WEEK 24

Increase

20.2

POINTS IMPROVEMENT
vs placebo through Week 24 (95% CI: 17.5, 23.0; P<0.0001)

  • In Trial 1, significant improvement in CFQ-R Respiratory Domain score was seen as early as Week 4
    •  20.1-point improvement vs placebo (95% CI: 16.9, 23.2; P<0.0001)

The MCID threshold for CFQ-R Respiratory Domain score is 4 points in patients with CF with stable respiratory symptoms and represents the minimal change a patient can detect.7

In Trial 1, mean baseline CFQ-R Respiratory Domain score was 68.3 for patients receiving TRIKAFTA and 70.0 for those receiving placebo.5

 

CFQ-R Respiratory Domain score measured composite patient-reported outcomes in the following respiratory symptoms8: 

  • Waking up from coughing
  • Wheezing
  • Coughing
  • Congestion
  • Difficulty breathing
  • Mucus production

Collapse

Back to Top

Significant increase in BMI at Week 241,2

SECONDARY ENDPOINT

ABSOLUTE CHANGE FROM BASELINE IN BMI

Increase

1.0

kg/m2 INCREASE VS PLACEBO AT WEEK 24
(95% CI: 0.85, 1.23; P<0.0001)

For example, if a patient weighs 130 lb and is 5'5" tall, then a 1.0-kg/m2 absolute change in BMI is equivalent to a 6-lb increase in weight.

In Trial 1, mean baseline BMI was 21.49 kg/m² (range: 15.01, 30.86) for patients receiving TRIKAFTA and 21.31 kg/m² (range: 14.42, 33.80) for patients receiving placebo.4

 

Collapse

Back to Top

BMI, body mass index; CF, cystic fibrosis; CFQ-R, Cystic Fibrosis Questionnaire-Revised; CFTR, cystic fibrosis transmembrane conductance regulator; CI, confidence interval; IV, intravenous; lb, pounds; LS, least squares; MCID, minimal clinically important difference; ppFEV1, percent predicted forced expiratory volume in 1 second; q12h, every 12 hours; qam, every morning; qpm, every evening; RR, rate ratio, SE, standard error; SwCl, sweat chloride; WK, week.

Trial 1
(Heterozygous F508del/Other Specific)

TRIAL 2: A double-blind, active-controlled, head-to-head Phase 3 trial in patients homozygous for the F508del mutation1,2

Study Design


Prior to the run-in period, all patients in this study discontinued previous CFTR modulator therapies, but remained on their standard-of-care CF therapies.1

aAll patients who completed the study were eligible to roll over into a 192-week, open-label extension study.1,3 
 

Key inclusion criteria1,2b 

  • Confirmed CF diagnosis, clinically stable, and at least 12 years of age
  • Homozygous for the F508del mutation
  • ppFEV1 between 40% and 90% at screening

bKey exclusion criteria included clinically significant cirrhosis with or without portal hypertension, a history of colonization with organisms associated with a more rapid decline in pulmonary status (including, but not limited to, Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium abscessus), and solid organ or hematologic transplantation.1,4

 

Primary endpoint1

  • Absolute change in ppFEV1 from baseline at Week 4
KEY SECONDARY ENDPOINTS1c

FROM BASELINE AT WEEK 4:

  • Absolute change in sweat chloride
  • Absolute change in CFQ-R Respiratory Domain score

cA hierarchical testing procedure was performed for key secondary endpoints. For an endpoint to be significant, both it and all previous tests in the hierarchy had to achieve a hierarchy of P<0.05.5

Baseline characteristics in Trial 26
TRIKAFTA
Tezacaftor/ivacaftor and ivacaftor
Sex, female, %
56.4
53.8
Mean age, years (range)
28.8 (12.7-54.1)
27.9 (12.4-60.5)
Mean BMI, kg/m2 (range)
21.8 (16.0-28.4)
21.9 (15.6-34.6)
Mean ppFEV1 (range)
61.6 (35.0-87.4)
60.2 (35.0-89.0)
Mean SwCI, mmol/L (range)
91.4 (67.0-114.0)
90 (60.5-112.0)
Back to Top

Summary of Efficacy Results

Significant improvements in lung function and sweat chloride vs active comparator1,2

PRIMARY ENDPOINT

ABSOLUTE CHANGE IN ppFEV1 FROM BASELINE

Increase

10.0

Percentage
Points

IMPROVEMENT vs tezacaftor/ ivacaftor and ivacaftor at Week 4 (95% CI: 7.4, 12.6; P<0.0001)

In Trial 2, mean baseline ppFEV₁ was 61.6 percentage points (range: 35.0, 87.4) for patients receiving TRIKAFTA and 60.2 percentage points (range: 35.0, 89.0) for patients receiving the active comparator.6

Collapse

SECONDARY ENDPOINT1

-45.1

mmol/L

SIGNIFICANT REDUCTION IN SWEAT CHLORIDE
Compared with tezacaftor/ ivacaftor and ivacaftor at Week 4 (95% CI: -50.1, -40.1; P<0.0001)

In Trial 2, mean baseline sweat chloride was 91.4 mmol/L (range: 67.0, 114.0) for patients receiving TRIKAFTA and 90.0 mmol/L (range: 60.5, 112.0) for patients receiving the active comparator.6

Back to Top

Significantly improved CFQ-R Respiratory Domain score vs active comparator1,2

SECONDARY ENDPOINT

Mean Absolute Change from Baseline in CFQ-R Respiratory Domain Score

Increase

17.4

POINTS IMPROVEMENT

vs tezacaftor/ivacaftor and ivacaftor at Week 4  (95% CI: 11.8, 23.0; P<0.0001)

The MCID threshold for CFQ-R Respiratory Domain score is 4 points in patients with CF with stable respiratory symptoms and represents the minimal change a patient can detect.7

In Trial 2, mean baseline CFQ-R Respiratory Domain score was 70.6 points for patients receiving TRIKAFTA and 72.6 points for those receiving the active comparator.6

 

CFQ-R Respiratory Domain score measured composite patient-reported outcomes in the following respiratory symptoms8: 

  • Waking up from coughing
  • Wheezing
  • Coughing
  • Congestion
  • Difficulty breathing
  • Mucus production

Collapse

Back to Top

BMI, body mass index; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CFQ-R, Cystic Fibrosis Questionnaire-Revised; CI, confidence interval; IV, intravenous; LS, least square; MCID, minimal clinically important difference; ppFEV1, percent predicted forced expiratory volume in 1 second; q12h, every 12 hours; qam, every morning; qpm, every evening; RR, rate ratio, SE, standard error; SwCl, sweat chloride; WK, week.

Trial 2
(Homozygous F508del Mutation)